Fig. 8.1 Types of familial hypercholesterolemias FH includes heterozygous FH (HeFH), the less severe form, with a prevalence of ~1:200–1:500, and homozygous FH (HoFH), a much rarer condition, with a…
© Springer International Publishing Switzerland 2015Maciej Banach (ed.)Combination Therapy In Dyslipidemia10.1007/978-3-319-20433-8_17 17. Conclusions and Take Home Message Maciej Banach1 (1) Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Zeromskiego 113, Lodz,…
© Springer International Publishing Switzerland 2015Maciej Banach (ed.)Combination Therapy In Dyslipidemia10.1007/978-3-319-20433-8_16 16. Drug Evaluation: Olmesartan Medoxomil + Rosuvastatin for the Treatment of Dyslipidemia and Concomitant Risk Factors: A Chance for Better Compliance? Joanna Gozdzikiewicz-Lapinska1 and…
Fig. 15.1 The benefits of fenofibrate/simvastatin combination therapy in different clinical dyslipidemic patterns Although some evidence suggests a possible heightened risk for myopathy and rhabdomyolysis [11], the combination of statin…
© Springer International Publishing Switzerland 2015Maciej Banach (ed.)Combination Therapy In Dyslipidemia10.1007/978-3-319-20433-8_14 14. The Cardiovascular Polypill in the Prevention of Cardiovascular Disease Melvin Lafeber1 (1) Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands…
Lipid (mg/dL) MDF (%) HELP (%) DALI (%) DSA (%) IA (%) LDL-C 56–62 55–61 53–76 49–75 62–69 Triglycerides 37–49 20–53 29–40 26–60 34–49 HDL-C 25–42 5–17 5–29 4–17 9–27…
Fig. 11.1 Mechanism of action of the main lipid-lowering nutraceuticals More clinical research is needed to clarify the potential role in therapy of some interesting nutraceuticals with strong preclinical evidence…
(1) Department of Hypertension, Medical University of Lodz, Lodz, Poland (2) Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital Campus, University College London Medical School, University College…
Trial Study population Dose of co-administered drug(s) Duration (median) Primary endpoint Results AIM-HIGH [12] n = 3414 Aged > 45 years, established CVD (documented stable CAD, cerebrovascular or carotid disease, or PAD)…
Fig. 7.1 Mechanism of action of statin and mipomersen. (a) Mipomersen specifically binds the apoB mRNA sequence to provide a substrate for RNase H, which hydrolyses the apoB mRNA strand…
